Pilot Evaluation of Thulium Laser Alone or in Combination With Broad Band Light for Treatment of Dermatologic Conditions
Primary Purpose
Dermatology/Skin - Other
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Thulium Laser
Sponsored by
About this trial
This is an interventional treatment trial for Dermatology/Skin - Other
Eligibility Criteria
Inclusion Criteria:
- Female or Male, 18 years and older
- Fitzpatrick Skin Type I-VI
- Subject has visible signs of moderate sun-damages and/or aging facial skin with visible areas of fine rhytides, pigmentation, and erythema or telangiectasia.
- Desires non-ablative photo-revitalization of the skin.
- Subject must agree to not make any changes in their skin regimen for the duration of the study, including the follow-up period.
- Subject must be able to read, understand and sign the Informed Consent Form.
- Must be willing and able to adhere to the treatment and follow-up schedule and post- treatment care instructions.
- Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period.
- Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
- Agree to not undergo any other procedure(s) in the treatment area during the study, such as laser- or light-based treatment, non-light based device treatment such as radiofrequency or ultrasound, injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler, chemical peel, or surgical procedure
Exclusion Criteria:
- Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.
- Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser or light-based procedures or surgery.
- Prior injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler in the target area within 1 week of study participation.
- History of malignant tumors in the target area.
- Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
- Pregnant and/or breastfeeding.
- Having an infection, dermatitis or a rash in the treatment area.
- Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
- Suffering from coagulation disorders or taking prescription anticoagulation medications.
- History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- History of vitiligo, eczema, or psoriasis.
- History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
- History of seizure disorders due to light.
- Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
- History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
- History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.
- History of pigmentary disorders, particularly tendency for hyper- or hypo- pigmentation.
- Systemic use of retinoid, such as isotretinoin, or corticosteroid, as applicable, within 6 months of study participation.
- Topical use of retinoid, such as isotretinoin, corticosteroid or hydroquinone on the target area within 1 month of participation.
- Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
- Excessively tanned in areas to be treated, or unable/unlikely to refrain from tanning during the study (for example, subject's occupation requires regular sun exposure).
- Current smoker or history of smoking within 6 months of study participation.
- Has infectious disease
- Has been on long-standing systemic steroids (e.g. Prednisone, Dexamethasone)
- Has medical condition that may affect wound healing
- As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Sites / Locations
- Refined Dermatology
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Thulium Device
Arm Description
1927 Laser Treatment
Outcomes
Primary Outcome Measures
Photography
Change in photography when compared to baseline using Physicians global assessement scale
Secondary Outcome Measures
Pain scores
Pain during treatment scored using Numeric pain scale 0-10, where 0 is least pain and 10 being maximum pain
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03944278
Brief Title
Pilot Evaluation of Thulium Laser Alone or in Combination With Broad Band Light for Treatment of Dermatologic Conditions
Official Title
Pilot Evaluation of Thulium Laser Alone or in Combination With Broad Band Light for Treatment of Dermatologic Conditions
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
April 12, 2019 (Actual)
Primary Completion Date
August 30, 2020 (Actual)
Study Completion Date
September 29, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sciton
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Evaluate the Thulium laser device for skin resurfacing procedures, or as a treatment for pigmented lesions (age or sun spots) or dyschromia; or cutaneous lesions such as, but not limited to, actinic keratosis, melasma, fine rhytides; or as a method of improving skin tone and skin texture
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dermatology/Skin - Other
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Thulium Device
Arm Type
Experimental
Arm Description
1927 Laser Treatment
Intervention Type
Device
Intervention Name(s)
Thulium Laser
Intervention Description
Thulium laser for skin resurfacing procedures
Primary Outcome Measure Information:
Title
Photography
Description
Change in photography when compared to baseline using Physicians global assessement scale
Time Frame
6 weeks post final treatment
Secondary Outcome Measure Information:
Title
Pain scores
Description
Pain during treatment scored using Numeric pain scale 0-10, where 0 is least pain and 10 being maximum pain
Time Frame
Immediately after each treatment received
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Female or Male, 18 years and older
Fitzpatrick Skin Type I-VI
Subject has visible signs of moderate sun-damages and/or aging facial skin with visible areas of fine rhytides, pigmentation, and erythema or telangiectasia.
Desires non-ablative photo-revitalization of the skin.
Subject must agree to not make any changes in their skin regimen for the duration of the study, including the follow-up period.
Subject must be able to read, understand and sign the Informed Consent Form.
Must be willing and able to adhere to the treatment and follow-up schedule and post- treatment care instructions.
Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period.
Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
Agree to not undergo any other procedure(s) in the treatment area during the study, such as laser- or light-based treatment, non-light based device treatment such as radiofrequency or ultrasound, injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler, chemical peel, or surgical procedure
Exclusion Criteria:
Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.
Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser or light-based procedures or surgery.
Prior injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler in the target area within 1 week of study participation.
History of malignant tumors in the target area.
Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
Pregnant and/or breastfeeding.
Having an infection, dermatitis or a rash in the treatment area.
Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
Suffering from coagulation disorders or taking prescription anticoagulation medications.
History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
History of vitiligo, eczema, or psoriasis.
History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
History of seizure disorders due to light.
Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.
History of pigmentary disorders, particularly tendency for hyper- or hypo- pigmentation.
Systemic use of retinoid, such as isotretinoin, or corticosteroid, as applicable, within 6 months of study participation.
Topical use of retinoid, such as isotretinoin, corticosteroid or hydroquinone on the target area within 1 month of participation.
Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
Excessively tanned in areas to be treated, or unable/unlikely to refrain from tanning during the study (for example, subject's occupation requires regular sun exposure).
Current smoker or history of smoking within 6 months of study participation.
Has infectious disease
Has been on long-standing systemic steroids (e.g. Prednisone, Dexamethasone)
Has medical condition that may affect wound healing
As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jay Patel
Organizational Affiliation
Sciton
Official's Role
Study Director
Facility Information:
Facility Name
Refined Dermatology
City
Los Gatos
State/Province
California
ZIP/Postal Code
95032
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Pilot Evaluation of Thulium Laser Alone or in Combination With Broad Band Light for Treatment of Dermatologic Conditions
We'll reach out to this number within 24 hrs